October 11 (SeeNews) - Bulgarian veterinary drug maker Biovet said on Tuesday its majority owner Huvepharma and minority shareholder Opportunity 2009 had raised their joint buyout bid for the remaining 677,998 shares which they do not already own to 15.03 levs per share ($8.5/7.7 euro) from 14.4 levs offered previously.
Jun 10, 2026
BucharestJun 30, 2026Marrakech
